Organization (Hospital)
Nemours Children's Health System
ClinicalTrials.gov lists Nemours Children's Health System as lead sponsor of 134 trials, counting the companies grouped under it. Nemours Children's Health System itself has 1 active development program.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 1.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo Dchasewiki, via Wikimedia Commons, CC BY-SA 4.0. Shown to identify the organization; it may be a registered trademark.
This page covers Nemours Children's Health System and 1 company grouped under it: 134 lead-sponsored trials (4 its own, 130 in the grouped companies) and 4 legal-entity registrations (1 its own, 3 in the grouped companies).
Companies grouped under this page (1)
| Company | Lead trials | Legal entities |
|---|---|---|
| Nemours Children’s Clinic | 130 | 3 |
Disease areas (138)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Diabetes Mellitus | 35 |
| Diabetes Mellitus, Type 1 | 28 |
| Obesity | 20 |
| Asthma | 14 |
| Anemia | 9 |
Showing 5 of 138 disease areas.
Trials by start year as sponsor or collaborator (9)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 1 |
| 2024 | 1 |
| 2023 | 1 |
| 2022 | 2 |
| 2021 | 1 |
| 2020 | 1 |
| 2019 | 2 |
| 2017 | 1 |
Recruitment duration, a model prediction: none of the 4 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (1)
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Standard Care | COVID-19 | Not reported | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 1 of 3 hit target (n=3) | 2 of 3 on time (n=3) |
Journals published in (240)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Pediatrics | 16 |
| The Journal of pediatrics | 13 |
| Journal of pediatric surgery | 12 |
| Diabetes care | 11 |
| The Journal of clinical endocrinology and metabolism | 11 |
Showing 5 of 240 journals.
Financing and grant events (21)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-07-24 | NIH grant | 527,712 | Reporter |
| 2025-03-31 | NIH grant | 167,076 | Reporter |
| 2024-08-22 | NIH grant | 619,440 | Reporter |
| 2024-08-13 | NIH grant | 277,540 | Reporter |
| 2024-04-11 | NIH grant | 167,076 | Reporter |
Showing 5 of 21 events.
Organization relationships (135)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Government of the United States of America | Co sponsors trial with | 9 |
| Children's Hospital of Philadelphia | Co sponsors trial with | 8 |
| Seattle Children's Hospital | Co sponsors trial with | 7 |
| Lurie Children's Hospital | Co sponsors trial with | 7 |
| University of Colorado System | Co sponsors trial with | 5 |
Showing 5 of 135 relationships.
Latest dated events (194)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-12 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-10-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-08-26 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-08-03 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-08-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 194 events.
Biomarker capability evidence (8)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| KIDINS220 | Trial collaborator | Named in trial inclusion criteria |
| DPP4 | Trial collaborator | Named in trial exclusion criteria |
| EPO | Trial collaborator | Named in trial exclusion criteria |
| SLC5A1 | Trial collaborator | Named in trial exclusion criteria |
| DPP4 | Trial collaborator | Mentioned in trial text |
Showing 5 of 8 evidence rows.
Biomarkers this organization publishes on (137)
Shown in this order: most publications first.
Showing 5 of 137 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, approved assets, us granted patents, sec-reported annual financials, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.